| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 159.40 | 2.4% | 36.1% |
| Total Income | 159.40 | 2.4% | 36.1% |
| Expenditure | 129.80 | 2.8% | 18.7% |
| PBT | 12.13 | 86.9% | 190.2% |
| Net Profit | 12.90 | 153.4% | 191.9% |
| OPM | 18.57% | 0.33pp | 12.00pp |
| NPM | 8.09% | 4.98pp | 20.08pp |
| EPS | 0.06 | 200.0% | 185.7% |
BioCryst Reports Q3 2025 Results: ORLADEYO Revenue $159.1M, Up 37% Y-o-Y
04 May 2026 · 4 May, 8:18 am
Summary
BioCryst Pharmaceuticals reported strong Q3 2025 financial results, driven by the continued growth of ORLADEYO, which saw a 37% increase in net revenue to $159.1 million. The company's operating profit increased significantly, and they raised their full-year revenue guidance for ORLADEYO to $590 to $600 million. BioCryst also completed the sale of its European ORLADEYO business and signed an agreement to acquire Astria Therapeutics. The company prepaid the remaining outstanding amount under the Pharmakon term loan of $198.7 million following the closing of the sale of its European ORLADEYO business.
Key Highlights
- 1
ORLADEYO net revenue for Q3 2025 reached $159.1 million, representing a 37 percent increase year-over-year.
- 2
The company's operating profit for Q3 2025 was $29.6 million, a 285 percent increase year-over-year.
- 3
Non-GAAP operating profit for Q3 2025 was $51.7 million, up 107 percent year-over-year, driven by strong operating leverage.
- 4
BioCryst raised its ORLADEYO FY 2025 revenue guidance to between $590 to $600 million.
- 5
The company lowered its FY 2025 non-GAAP operating expense guidance to between $430 to $440 million.
- 6
BioCryst completed the sale of its European ORLADEYO business and used the proceeds to retire all remaining Pharmakon term debt.
- 7
A definitive agreement was signed to acquire Astria Therapeutics, with the transaction expected to close in Q1 2026.
Management Comments
Jon Stonehouse
BioCryst’s excellent performance this quarter was driven by the continued momentum of ORLADEYO, which delivered impressive growth. We’ve recently made two strategic moves that are transformative for our company: the sale of our European ORLADEYO business, which strengthened our margins and financial position and enabled us to pay off our debt, and the proposed acquisition of Astria, which we believe gives us the incredible opportunity to help even more HAE patients and drive sustainable growth and profitability well into the next decade. It has been an incredible honor to lead the employees of BioCryst over these past nearly 19 years. I couldn’t be more confident in the exceptional team we have built and am excited to see them take BioCryst forward and continue to deliver innovative treatments for patients living with rare diseases.
Charlie Gayer
ORLADEYO demand remained strong in the third quarter, with new patient adds and prescriber confidence driving continued growth. Even with the market entry of new prophylactic therapies, ORLADEYO remains the most differentiated option for patients and our commercial results are strong evidence of this. We’re not resting on our success though: we’re excited about the possibility to bring ORLADEYO granules to kids with HAE in the near-term as well as potentially expanding our HAE portfolio with navenibart. Our team’s continuing focus on execution and innovation is improving our ability to help more patients in the HAE community, now and for years to come
Informational and educational content only. Not investment advice.